Coblopasvir

Coblopasvir is a pharmaceutical drug for the treatment of hepatitis C.^[1] It is a pan-genotypic inhibitor of HCV nonstructural protein 5A.^[2]

Coblopasvir

Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name Methyl N-[(2S)-1-[(2S)-2-[5-[4-[7-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]-1,3-benzodioxol-4-yl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate
CAS Number	1312608-46-0
PubChem CID	58316387
DrugBank	DB15315
ChemSpider	75531292
UNII	67XWL3R65W
KEGG	D12247
Chemical and physical data
Formula	C41H50N8O8
Molar mass	782.899 g·mol−1
InChI InChI=InChI=1S/C41H50N8O8/c1-22(2)32(46-40(52)54-5)38(50)48-17-7-9-30(48)36-42-19-28(44-36)25-13-11-24(12-14-25)26-15-16-27(35-34(26)56-21-57-35)29-20-43-37(45-29)31-10-8-18-49(31)39(51)33(23(3)4)47-41(53)55-6/h11-16,19-20,22-23,30-33H,7-10,17-18,21H2,1-6H3,(H,42,44)(H,43,45)(H,46,52)(H,47,53)/t30-,31-,32-,33-/m0/s1 Key:JBYJTCVXUMWTJJ-YRCZKMHPSA-N

In China, it is approved for use in combination with sofosbuvir for treating naïve or interferon‐experienced adults chronically monoinfected patients with HCV of genotype 1, 2, 3 and 6, with or without compensated cirrhosis.^[2]